Success Metrics

Clinical Success Rate
87.5%

Based on 21 completed trials

Completion Rate
88%(21/24)
Active Trials
2(7%)
Results Posted
67%(14 trials)
Terminated
3(11%)

Phase Distribution

Ph phase_3
6
22%
Ph early_phase_1
1
4%
Ph phase_2
2
7%
Ph phase_1
3
11%
Ph phase_4
9
33%
Ph not_applicable
3
11%

Phase Distribution

4

Early Stage

2

Mid Stage

15

Late Stage

Phase Distribution24 total trials
Early Phase 1First-in-human
1(4.2%)
Phase 1Safety & dosage
3(12.5%)
Phase 2Efficacy & side effects
2(8.3%)
Phase 3Large-scale testing
6(25.0%)
Phase 4Post-market surveillance
9(37.5%)
N/ANon-phased studies
3(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

21 of 24 finished

Non-Completion Rate

12.5%

3 ended early

Currently Active

2

trials recruiting

Total Trials

27

all time

Status Distribution
Active(2)
Completed(21)
Terminated(3)
Other(1)

Detailed Status

Completed21
Terminated3
unknown1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
2
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.2%)
Phase 13 (12.5%)
Phase 22 (8.3%)
Phase 36 (25.0%)
Phase 49 (37.5%)
N/A3 (12.5%)

Trials by Status

unknown14%
active_not_recruiting14%
completed2178%
recruiting14%
terminated311%

Recent Activity

2 active trials
Showing 5 of 27
active_not_recruitingearly_phase_1

Vyvanse in Children Aged 6 to 12 Years

NCT05416125
completedphase_3

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment

NCT03926052
recruitingphase_2

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

NCT06847399
completedphase_4

Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome

NCT01071044
completed

Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine

NCT03497169
View all 27 trials

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT05416125Early Phase 1

Vyvanse in Children Aged 6 to 12 Years

Active Not Recruiting
NCT03926052Phase 3

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment

Completed
NCT06847399Phase 2

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

Recruiting
NCT01071044Phase 4

Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome

Completed
NCT03497169

Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine

Completed
NCT01342445Phase 4

Effects of LDX on Functioning of College Students With ADHD

Completed
NCT03924193Phase 3

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment

Completed
NCT03337646Phase 4

Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism

Completed
NCT04946461

The Day-time Response Variation of (Lis)Dexamphetamine

Completed
NCT03333668Not Applicable

Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents

Unknown
NCT04152629Phase 4

Real World Evidence of the Efficacy and Safety of FOQUEST

Completed
NCT02009163Phase 3

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Completed
NCT00746733Phase 1

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC

Completed
NCT01106430Phase 3

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Completed
NCT01552902Phase 4

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Completed
NCT01328756Phase 4

Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT00776555Phase 1

Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution

Terminated
NCT01657019Phase 3

Open Label Extension in Adults With Binge Eating Disorder (BED)

Completed
NCT01552915Phase 4

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Completed
NCT01890785Phase 1

Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers

Completed

Drug Details

Intervention Type
DRUG
Total Trials
27